Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Partial 17q gain resulting from isochromosomes, unbalanced translocations and complex rearrangements is associated with gene overexpression, older age and shorter overall survival in high hyperdiploid childhood acute lymphoblastic leukemia Leukemia (2013) 27, 493-496; doi:10.1038/leu. 2012.198 High hyperdiploid acute lymphoblastic leukemia (ALL) is associated with a B-cell precursor (BCP) immunophenotype, low white blood cell count, age between 3 and 5 years, and a favorable prognosis. 1 It is characterized by 51-67 chromosomes, with nonrandom trisomies and tetrasomies. Interestingly, partial gains of the common extra chromosomes are rare, 1 with the exception of chromosome 17, which is trisomic in 75% of cases and forms an isochromosome resulting in 17q gain and 17p loss in an additional 2-5% of cases. 2, 3 We recently reported that partial gains of 17q is present in 9% of high hyperdiploid ALL as detected by singlenucleotide polymorphism (SNP) array analysis. 4 Surprisingly, the majority of these 17q gains did not seem to arise from i(17q). We have now further characterized rearrangements with breakpoints in chromosome 17, screened for TP53 mutations, and investigated the gene expression in high hyperdiploid pediatric BCP ALL (Table 1; Supplementary Table 2) . Cases were included if they had uniparental disomy (UPD) or trisomy (UPT) involving 17p, had a 17p deletion, or gain of 17q not associated with trisomy 17, as ascertained by SNP array analysis. For cases 1-11, which were included in a series of 74 high hyperdiploid patients, 4 SNP array results have been previously published. Diagnostic bone Accepted article preview online 17 July 2012; advance online publication, 24 August 2012
Letters to the editor marrow samples from cases 12-14 were part of a cohort of six high hyperdiploid cases analyzed using the Illumina 1M-quad bead Infinium BD BeadChip platform (Illumina, San Diego, CA, USA) as previously described 4 (Supplementary Tables 1 and 2) Figure 1a ; Supplementary Figure 1 ; Supplementary Table 1) .
In total, we observed partial 17q gain in 12 (15%) of a consecutive series of eighty diagnostic samples investigated with SNP array analysis, making partial 17q gains the second most common secondary abnormality after dup(1q) in high hyperdiploid ALL. 1 In all cases where material was available, metaphase fluorescence in situ hybridization was performed according to standard methods on bone marrow or peripheral blood cells, utilizing probes for centromere 17, the subtelomeric regions of 17p and 17q, TP53, and various whole chromosomes (Abbott Molecular, Des Plaines, IL, USA). Together with G-banding and SNP array data, these analyses showed that four cases harbored an idic(17)(p11.2), two had gained a del(17)(p11.2), three had unbalanced translocations leading to 17q gain, and one had a complex rearrangement resulting in three copies for most of the chromosome 17 (Table 1 ; Supplementary Figure 1) ; no recurrent rearrangement was seen. The 17q gains thus arose by several different mechanisms, which could explain why partial 17q gains apart from i(17q) have not been recognized as a distinct abnormality in previous studies. Alternatively, the frequency may differ in different patient cohorts. We therefore analyzed the SNP array data reported by Mullighan et al. 5 and found 17q gains not due to þ 17 in 3/39 (7.7%; #15, 21, and 32) of the cases (data not shown); a somewhat lower frequency than in the present analysis.
Isochromosome 17q has been detected by G-banding analysis in 2-5% of high hyperdiploid ALL, 2,3 agreeing well with our finding of 4/80 (5.0%) cases (Table 1 ). All our cases had breakpoints in 17p11.2 and were hence in fact isodicentric chromosomes. Two cases had breakpoints at 19.0-19.1 Mb, which has been reported to be a breakpoint cluster region characterized by palindromic repeats in chronic myeloid leukemia and medulloblastoma with idic(17p11), and two at 21.2-21.7 Mb, which corresponds to a region involved in idic(17p11)-positive medulloblastoma. 6, 7 We have previously suggested that trisomy 17 and i(17q)/idic(17p11) are mutually exclusive. 1 However, case 3 in the present study had retained two normal copies of chromosome 17, in effect refuting this hypothesis.
Four cases had unbalanced translocations or complex rearrangements resulting in 17q gains (Table 1) . Case 4 had a breakpoint in or close to BRCA1, which is mutated in hereditary breast cancer; it has not, however, been previously implicated in ALL. 8 In case 6, the breakpoint occurred in or close to IKZF3, a transcription factor involved in lymphoid differentiation which is deleted in B2% of pediatric ALL. 5 Case 10 had a breakpoint in TAOK1, which has been Letters to the editor reported to be fused out-of-frame with PAX5 in one BCP ALL; 9 however, there was no indication of PAX5 rearrangements in this case. The remaining breakpoints were in genes that have previously not been implicated in neoplasia.
Of the 80 high hyperdiploid ALL cases that we have investigated at diagnosis, 4 66% had gained a whole extra chromosome 17 and 15% parts of 17q. Thus, there is a strong selection for gain of 17q material in high hyperdiploid ALL. To investigate the expression pattern on chromosome 17, global gene expression analysis was performed using the Human HT-12 v4 Expression BeadChip (Illumina) according to the manufacturer's instructions in 43 cases of high hyperdiploid childhood ALL, including #2, 5, 7, 8, 12 and 13 from the present study. Quantile normalization was done using BioArray Software Environment (BASE). 10 To identify chromosomal regions differentially expressed in cases with trisomy 17 and partial gain of 17q, Gene Set Enrichment Analysis (GSEA) was performed on normalized data from BASE using default settings 11 in the 30 cases with trisomy 17 (n ¼ 26) or partial gain of 17q (#2, 7, 12 and 13); genes were classified according to the positional gene set (C1) in the Molecular Signatures Database (http://www.broadinstitute.org/ gsea/msigdb/index.jsp). Although the expression 17p genes was lower in cases with partial 17q gains, 17q genes had a similar expression (Figure 1b ) and GSEA showed a significant enrichment of genes in 17p13 and 17p11 (false discovery rate (FDR) ¼ 0.002; Po0.001 and FDR ¼ 0.020; Po0.001, respectively) in cases with trisomy 17. The global gene expression analysis thus showed that genes on 17q display a similar expression in cases with trisomy 17 and partial 17q gain ( Figure 1b) ; it is hence likely that the pathogenetic outcome of these two types of aberration is similar. The high frequency of þ 17 in high hyperdiploid ALL and the large minimally gained region (B40 Mb) make it unlikely that a specific gene is targeted. Instead, the result may be large-scale gene dosage effects affecting leukemogenesis. As regards loss of 17p, four cases had deletion and four cases had a UPD/UPT including parts of 17p. As deletions and UPDs/UPTs may render a mutation homozygous, we sequenced all coding exons of TP53, which is located in the minimally deleted region, in cases 1-13. However, no mutation was found.
To investigate whether 17q gains were associated with clinical factors, cases with partial 17q gain were compared with other high hyperdiploid ALL in our patient series that had been analyzed by On 17p, where cases with partial 17q gain have one or two copies, the mean gene expression was notably lower in the partial 17q cases. On 17q, of which both cases with partial 17q gains and trisomy 17 have three copies, the mean gene expression was similar in both groups.
SNP array, 4 in total 80 cases (Supplementary Table 1 ). Only patients that had been treated within the Nordic Society for Pediatric Hematology and Oncology ALL 1992/2000 protocols were included in the survival analyses, comprising 48 cases including cases 2-4, 7 and 9. The probabilities of 5 years eventfree survival (pEFS) and overall survival (pOS) were calculated using the Kaplan-Meier method; groups were compared with the log rank test. There were no differences in gender distribution (P ¼ 0.343; two-tailed Fisher exact probability test), white blood cell count (P ¼ 0.803; two-sided Mann-Whitney test), or pEFS (partial 17q gains: 0.60, SE 0.22; no partial 17q gains: 0.78, SE 0.07; P ¼ 0.292) but patients with partial 17q gain were significantly older, with a median age of 6.5 years (range 3-13 years) at diagnosis compared with 3 years (range 1-16 years) for those without partial 17q gain (P ¼ 0.0128; two-sided Mann-Whitney test), and had a lower pOS (partial 17q gains: 0.60, SE 0.22; no partial 17q gains: 0.93, SE 0.04; P ¼ 0.0200). Although based on a small number of cases, this suggests that partial 17q gain is a marker for poor prognosis, in line with some previous reportsalbeit debated-of a poor outcome in i(17q)-positive high hyperdiploid childhood ALL. 2, 3, 12 To ascertain whether partial 17q gains may be more common in relapsing high hyperdiploid ALL, we investigated published series of SNP array data, finding that 1/6 (17%) cases reported by Mullighan et al. 13 had partial 17q gain at diagnosis versus 2/6 (33%) at relapse, and 6/16 (38%) versus 8/16 (50%) cases reported by Inthal et al.
14 On the other hand, none of the 11 relapse cases investigated by us displayed partial 17q gains. 15 Taken together, however, there may be an increased frequency of partial 17q gain in relapsing high hyperdiploid ALL already at the time of diagnosis, becoming even more common at relapse.
In summary, we have shown that partial gain of 17q, arising through different types of chromosomal rearrangements, is a recurrent aberration in high hyperdiploid childhood ALL. The most likely pathogenetic outcome is dosage effects of genes on 17q, possibly in addition to an as yet unidentified mutation in 17p. Furthermore, the aberration may be associated with a decreased pOS and relapsing ALL.
